Stock events for GRAIL, Inc. (GRAL)
GRAIL's stock experienced volatility in the past six months. In February 2026, the stock plummeted despite beating EPS estimates due to mixed results from the NHS-Galleri trial. Prior to this, the stock had appreciated due to positive data from the PATHFINDER 2 study and investor optimism following third-quarter results in November 2025. GRAIL submitted its Premarket Approval application for the Galleri test to the FDA in January 2026.
Demand Seasonality affecting GRAIL, Inc.’s stock price
The provided information does not explicitly detail demand seasonality for GRAIL, Inc.'s products and services. However, the company has reported consistent revenue growth for its Galleri test across different quarters, indicating ongoing demand. Over 325,000 Galleri tests have been prescribed since its commercial launch in 2021, with increasing repeat test volumes, suggesting a steady and growing adoption rather than pronounced seasonal fluctuations.
Overview of GRAIL, Inc.’s business
GRAIL, Inc. is a healthcare company focused on early cancer detection through next-generation sequencing, clinical studies, machine learning, and automation. Their main product is the Galleri test, a multi-cancer early detection blood test, and they also offer DAC, a diagnostic aid for cancer tests, along with development services for clinical studies.
GRAL’s Geographic footprint
GRAIL, Inc. is headquartered in Menlo Park, California, and operates in the United States and internationally, including research and operations centers in the United Kingdom.
GRAL Corporate Image Assessment
GRAIL's brand reputation has faced mixed perceptions due to the outcomes of its clinical trials. The NHS-Galleri trial's failure to meet its primary endpoint led to negative market reactions, while the company emphasizes the clinical performance of Galleri and its FDA Premarket Approval Application. GRAIL faced discontent and legal action from investors as of 2024.
Ownership
GRAIL, Inc. has a diverse ownership structure including institutional, retail, and individual investors. Institutional investors hold between 21.59% and 70.27% of the stock, insiders own around 21.22%, and public companies and individual investors hold between 13.34% and 43.85%. Major institutional shareholders include BlackRock, Inc., Farallon Capital Management Llc, Baker Bros. Advisors Lp, Vanguard Group Inc, Primecap Management Co/ca/, State Street Corp, Morgan Stanley, and Illumina, Inc.
